Mizuho Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $41

Benzinga Newsdesk www.benzinga.com Positive 77.7%

Neg 0% Neu 0% Pos 77.7%

Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and raises the price target from $20 to $41.